Screen for CRC with a proven blood test.

  • Proven Performance
    • 90%+ adherence1* and 2x+ screening increase2,3†
    • 100% accuracy in Stages II, III, and IV4
    • 100,000+ Shield blood tests have been completed since FDA approval5
  • Published and Guideline Included
    • Recommended in ACS Guidelines for CRC screening6‡
    • Recommended by the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®)7
    • Published in the NEJM4
  • Powered by Guardant Health
    • Shield is backed by Guardant’s 10+ years of experience and 1+ million blood tests performed5
  • Proven Performance
    • 90%+ adherence1* and 2x+ screening increase2,3†
    • 100% accuracy in Stages II, III, and IV4
    • 100,000+ Shield blood tests have been completed since FDA approval5

*For eligible patients

  • Published and
    Guideline Included
    • Recommended in ACS Guidelines for CRC screening6‡
    • Recommended by the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®)7
    • Published in the NEJM4
  • Powered by
    Guardant Health
    • Shield is backed by Guardant’s 10+ years of experience and 1+ million blood tests performed5

“I've had a lot of success getting patients to screen with Shield.”

— Yulia Koltzova-Rang, MD

Internal Medicine*

*Dr. Yulia Koltzova-Rang is a paid consultant of Guardant Health.

*Dr. Yulia Koltzova-Rang is a paid consultant of Guardant Health.

Simplify CRC screening
with the Shield™ blood test

  • Create the
    Order

    a Shield order

  • +

  • Collect Blood
    Sample

    the patient’s
    blood sample with only two tubes

  • =

  • Complete

    by shipping the sample, and receive results within ~2 weeks

Choose how you’d like to start
Receive two Shield™ blood collection kits when you download Shield Order Form or Register practice.

Register Practice
Order via Shield Portal or your EHR

Not sure what to choose?
Select "Shield Portal" to register or click "Contact Me" below and we will be in touch to help.

Download Order Form
Get the Shield test requisition form

 Access through

Search "Shield" to order
in Quanum® Lab Services Manager
or your EHR or enter test code 18441
Order Kits
Questions? Request a Call
Shield is performed and billed through Guardant Health.

Thank you for sharing
your information
A team member will reach out within 2 business days.

Oops!
Please check your information and try again.

Retry

  • Contact Me
    We'll reach out to get you started

    Thank you for sharing
    your information
    A team member will reach out within 2 business days.

    Oops!
    Please check your information and try again.

    Retry
Back

Important Product Information

Intended Use

The Shield™ test is a qualitative, in vitro diagnostic test intended to detect colorectal cancer derived alterations in cell-free DNA from blood collected in the Guardant Shield Blood Collection Kit.
Shield is intended for colorectal cancer screening in individuals at average risk for the disease, age 45 years or older. Patients with a positive result should be followed by colonoscopy. Shield is not a replacement for diagnostic colonoscopy or for surveillance colonoscopy in high-risk individuals. This test is performed at Guardant Health, Inc.

Precaution: Based on data from clinical studies, Shield has limited detection (55%-65%) of Stage I colorectal cancer and does not detect 87% of precancerous lesions. One out of 10 patients with a negative Shield result may have a precancer that would have been detected by a screening colonoscopy. Shield demonstrated high detection of Stages II, III, and IV colorectal cancer.

Limitations and Other Important Information: The Shield test is not intended for patients that have personal history of colorectal cancer, adenomas, or other related cancers; or those who had a positive result on another colorectal cancer screening method within the last six months, have been diagnosed with a condition associated with high risk for colorectal cancer such as Inflammatory Bowel Disease (IBD), chronic ulcerative colitis (CUC), Crohn’s disease; or who have a family history of colorectal cancer, or certain hereditary syndromes. Providers should discuss the most appropriate screening test to use with patients depending on their medical history and individual circumstances. Shield may produce a false negative or false positive result. A false negative result may occur when the Shield test does not detect a colorectal tumor signal while a colonoscopy identifies a colorectal cancer. A negative result does not guarantee the absence of colorectal cancer or advanced adenoma, and patients should continue participating in colorectal cancer screening programs at the appropriate guideline-recommended intervals. A false positive result may occur when the Shield test generates a positive result while a colonoscopy will not find colorectal cancer or advanced adenoma.

Please read our Patient Fact Sheet (opens in a new window) for complete product information about the Shield test including full safety information.

Shield is available by prescription only.

NCCN=National Comprehensive Cancer Network®; NEJM=New England Journal of Medicine.
Recommended by the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Colorectal Cancer Screening as a CRC screening option. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.

Shield is not a replacement for diagnostic colonoscopy or for surveillance colonoscopy in high-risk individuals.

*Data from real-world clinical settings between May 2022 and June 2024 based on Laboratory Developed Test (LDT) usage of Shield, prior to FDA approval.

†Based on 2 studies. Study 1 compared screening completion with “usual care” (fecal immunochemical test [FIT] and colonoscopy), and an “intervention” (usual care + Shield) in over 1000 patients, age 45-75 years, who initially were offered but did not complete FIT in the previous 3 to 9 months at a large, integrated health system. Study 2 compared adherence to standard of care vs Shield use in <250 patients age 45-84 years at 2 primary care clinics affiliated with a large, not-for-profit integrated regional health system. All data based on LDT usage of Shield in 2022 and 2023 (Study 1) and 2024 (Study 2), prior to FDA approval.

‡ACS recommends blood-based CRC screening tests only to individuals who decline or have not completed a visual examination or stool-based test.

  1. References:
  2. Graham-Adderton C, Guerra CE, Ngo-Metzger Q, Hoang T, Raymond VM. Implementation of blood-based colorectal cancer screening: real-world adherence and outcomes. Curr Med Res Opin. 2025;41(10):1915-1920. doi:10.1080/03007995.2025.2582257
  3. Coronado GD, Jenkins CL, Shuster E, et al. Blood-based colorectal cancer screening in an integrated health system: a randomised trial of patient adherence. Gut. 2024;73(4):622-628. doi:10.1136/gutjnl-2023-330980
  4. Haynes WB Jr, Talari MP, Elmore KA, Jastan RM, Resil JJL. Blood-based colorectal cancer screening: implementation into 2 Appalachian primary care clinics. Am J Prev Med. 2025;69(1):107636. doi:10.1016/j.amepre.2025.04.006
  5. Chung DC, Gray DM II, Singh H, et al. A cell-free DNA blood-based test for colorectal cancer screening. N Engl J Med. 2024;390(11):973-983. doi:10.1056/NEJMoa2304714
  6. Data on file. Guardant Health, Inc.
  7. Wolf AMD, Hoffman RM, Walter LC, et al. Colorectal cancer screening: an update to the American Cancer Society guideline, 2026. CA Cancer J Clin. 2026;76(3):e70083. doi:10.3322/caac70083
  8. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology® (NCCN Guidelines®) for Colorectal Cancer Screening. V.2.2026. © National Comprehensive Cancer Network, Inc. 2026. All rights reserved. Accessed May 22, 2026. To view the most recent and complete version of the guideline, go to NCCN.org.
Call to Order